The Autoimmune Registry
Guillain-Barré syndrome Graphs for this disease are generated based on data from the All of Us database.
For more information on our data sources, please visit here.
For help with understanding the disease profile tabs and charts, please visit here.
  • Names
    • Guillain-Barré syndrome
    • Acute motor axonal neuropathy (subtype)
    • Axonal Guillain-Barré syndrome (subtype)
    • Fisher syndrome
    • Guillain-Barre Syndrome
    • Miller Fisher syndrome (subtype)
    • Miller-Fisher syndrome
    • Progressive inflammatory neuropathy (subtype)
    Abbreviations: GBS, MFS
    Category: Nervous System
    Incidence From 2,066 to 8,865 cases in the US per year (Sejvar 2011). Female/Male ratio: 1.4x.
    Age of Onset Onset typically occurs between ages 30 and 50.
    Description Guillain–Barré syndrome (GBS) is a rare autoimmune disorder in which the immune system attacks and damages the protective covering (myelin) of the nerves in the peripheral nervous system. Damage to the myelin hinders communication between the brain and the body, leading to muscle weakness or tingling sensations in the arms and legs. The cause of GBS is unknown but may be associated with a viral or bacterial infection, injury, or surgery. There are 6 types of GBS:

    Acute inflammatory demyelinating polyneuropathy is the most prevalently diagnosed form of GBS in the US and is often associated with a prior infection. This type leads to damage to the nerve myelin, but prognosis is good and full recovery is expected.

    Acute motor axonal neuropathy is associated with a prior infection causing diarrhea and is most common in children. This type primarily leads to weakness, which impairs movement and breathing and may lead to respiratory failure if untreated. Patients receiving medical attention are expected to recover.

    Acute motor-sensory axonal neuropathy is associated with prior infection causing diarrhea and has a sudden, intense onset. This type is most prevalent in adults. In addition to severe muscle weakness, patients also experience impairments in the senses. Prognosis is poor.

    Miller-Fisher syndrome is rare and results in difficulties with coordination, loss of reflexes, and paralysis around the eyes, along with impairments in the senses. Recovery is expected in 1 to 3 months.

    Acute panautonomic neuropathy is very rare and impairs both voluntary and involuntary body functions, including drops in blood pressure when standing, incontinence, lack of sweating, dry eyes and mouth, and impaired pupil function. Many patients experience heart problems, which can be fatal. Patients may improve, but slowly and incompletely.

    Pure sensory GBS causes the sudden appearance of impairments in the senses and loss of reflexes caused by damage to the myelin. Recovery is expected.

    Evidence of autoimmunity: Antibody
    ICD-10 Code: G61.0     SNOMED Code: 40956001

    Patient Groups
    Bloggers
    Symptoms
    Resources Link to Clinical Trials
    Link to PubMed
    References Link to Mayo Clinic
    Link to Cleveland Clinic
    Link to Healthline
    Profile by: Emily Romanello
  • Profile updated September 2024
  • Charts generated Oct 12, 2024 at 12:54 PM ET

  • Guillain-Barré syndrome sex breakdown


    Guillain-Barré syndrome age breakdown


    Patient ethnicities



    Join the registry!

    Data Source: Graphs on this page represent data in electronic health records and self-reported survey results from the All of Us research database. As of July 2024, there are 451,000 sets of electronic health records and over 560,000 participants who have completed initial survey questions. This dataset, however, may not be representative of the US population. A snapshot of the data can be found here. To protect participant anonymity, results derived from fewer than 20 participants are not graphed.
    The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants.

  • Guillain-Barré syndrome top comorbidities/symptoms

    Guillain-Barré syndrome top autoimmune comorbidities


    Join the registry!

    * Disease is suspected as autoimmune, but unconfirmed.
    Data Source: Graphs on this page represent data in electronic health records from the All of Us research database. As of July 2024, there are 451,000 sets of electronic health records collected from participants. In the United States, because electronic health records use billing codes for diagnoses, some conditions may not be perfectly captured by these data, especially if the condition is rare. A snapshot of the data can be found here. To protect participant anonymity, results derived from fewer than 20 participants are not graphed.
    The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants.

  • Anti-inflammatory / specialty medications and supplements

    Guillain-Barré syndrome top immunosuppressants / autoimmune therapies


    Join the registry!

    * Biologic medications.
    Data Source: Graphs on this page represent data in electronic health records from the All of Us research database. As of July 2024, there are 451,000 sets of electronic health records collected from participants. A snapshot of the data can be found here. To protect participant anonymity, results derived from fewer than 20 participants are not graphed.
    The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants.


  • Patient-reported 7-day average pain
    Chart is omitted due to low report count.


    Patient-reported 7-day average fatigue


    General physical health


    General mental health


    Social and relationship satisfaction


    General quality of life


    Ability to carry out social roles and activities


    Join the registry!

    Data Source: Graphs on this page represent data in self-reported survey results from the All of Us research database. As of July 2024, there are 560,000 participants who have completed these surveys. This dataset, however, may not be representative of the US population. A snapshot of the data can be found here. To protect participant anonymity, results derived from fewer than 20 participants are not graphed.
    The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants.


  • Concerns about ability to pay


    Feeling unheard by healthcare providers
    Chart is omitted due to low report count.


    Patient employment status


    Patient insurance coverage


    Join the registry!

    Data Source: Graphs on this page represent data in electronic health records and self-reported survey results from the All of Us research database. As of July 2024, there are 451,000 sets of electronic health records and over 560,000 participants who have completed initial survey questions. This dataset, however, may not be representative of the US population. A snapshot of the data can be found here. To protect participant anonymity, results derived from fewer than 20 participants are not graphed.
    The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants.